Ayman Fareed, MD
Addiction Psychiatry · Dahlonega, GANPI 1710997069
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,063, more than ten times the $39 reported in 2019.
Across 67 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$358
- Braeburn Inc.$325
- Otsuka America Pharmaceutical, Inc.$158
- Corium, LLC$156
- Alkermes, Inc.$131
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$121
- plus $317 from 8 others
Across 127 payments — averaging $430.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$55K
What the payments were for
- Food & beverage$1,566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 16 | $358 |
| Braeburn Inc. | 13 | $325 |
| Otsuka America Pharmaceutical, Inc. | 6 | $158 |
| Corium, LLC | 6 | $156 |
| Alkermes, Inc. | 5 | $131 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $121 |
| Johnson & Johnson | 4 | $93 |
| Tris Pharma Inc | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Lundbeck LLC | 1 | $32 |
| AbbVie | 2 | $32 |
| Noven Therapeutics, LLC | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
How this compares
$1,566 in reported general payments places this provider in the 80th percentile of 22 addiction psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $395 |
| Mirtazapine | 12 | $150 |
Paid to pharmacies, not to this prescriber.
Other addiction psychiatry in Dahlonega
- Vinay NagarajSuwanee$9K
- Michael VaughnDecatur$6K
- Kambiz AflatoonLawrenceville$4K
- Paige MarnellSavannah$3K
- William ColemanAlbany$1K
- John MoseriDecatur$1K
- Theodore SmithAtlanta$867
- Darvin HegeAtlanta$606
- Constantine GalifianakisAtlanta$588
- Susan BlankLawrenceville$377
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.